葡萄牙 ETICC 研究结果:2020 年 COVID-19 大流行对葡萄牙医院结直肠癌诊断和管理的影响。

IF 1 Q4 GASTROENTEROLOGY & HEPATOLOGY GE Portuguese Journal of Gastroenterology Pub Date : 2023-07-19 eCollection Date: 2024-08-01 DOI:10.1159/000531234
Maria Ana Rafael, Cristiana Sequeira, Sónia Isabel da Silva Barros, Bárbara Silva Abreu, Cristina Teixeira, Pierre Lahmek, Marine Besnard, Bruno Lesgourgues
{"title":"葡萄牙 ETICC 研究结果:2020 年 COVID-19 大流行对葡萄牙医院结直肠癌诊断和管理的影响。","authors":"Maria Ana Rafael, Cristiana Sequeira, Sónia Isabel da Silva Barros, Bárbara Silva Abreu, Cristina Teixeira, Pierre Lahmek, Marine Besnard, Bruno Lesgourgues","doi":"10.1159/000531234","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The outbreak of coronavirus disease 2019 (COVID-19) had affected clinical practice in several ways, including the restriction of nonessential endoscopic procedures. Therefore, our aim was to evaluate how colorectal cancer (CRC) diagnosis and management was affected during the first year of pandemics in Portugal.</p><p><strong>Methods: </strong>This is a Portuguese substudy of the French retrospective multicentric study ETICC (<i>Etude de l'Impact de la pandémie COVID-19 sur le diagnostic et la prise en charge du Cancer Colorectal</i>). We compared patients' characteristics, clinical manifestations, CRC staging at diagnosis, delay to first medical appointment, histological diagnosis, surgical and medical treatments between the year previous to the pandemics (control) and the first year of pandemics.</p><p><strong>Results: </strong>We included 766 patients: 496 in the control group and 270 in the COVID group. There was no significant difference in CRC staging at diagnosis between both groups, with 21% being diagnosed as metastatic in the control group and 22% in the first year of pandemics (<i>p</i> = 0.770). Contrary to what happened in France, there was a significant decrease in CRC diagnosis in asymptomatic patients (25-8.4%; <i>p</i> < 0.001) and after a positive fecal immunochemical test (20.8-11.3%; <i>p</i> = 0.002) during the pandemics. Although the increase in the overall complication rate at diagnosis was nonsignificant, in Portugal, there was a significant increase in diagnosis of abdominal occlusion (12.1-18.1%; <i>p</i> = 0.033). In Portugal, time between the beginning of symptoms and the first medical appointment significantly increased from a median of 50 days to 64 days during COVID (<i>p</i> < 0.001). On the contrary, time between histological diagnosis and tumor resection had significantly decreased from a median of 65 to 39 days (<i>p</i> < 0.001). Time between histological diagnosis and neoadjuvant treatment was not statistically different (median of 64-67 days; <i>p</i> = 0.590), as was time between histological diagnosis and palliative chemotherapy (median of 50-51 days; <i>p</i> = 1.000). Time from CRC resection and adjuvant treatment has significantly decreased from a median of 54 to 43 days (<i>p</i> = 0.001).</p><p><strong>Discussion: </strong>We found a significant impact in CRC diagnosis in the first year of pandemics, more pronounced than what was found in France. These are likely related not only with the closing of endoscopy units but also with the difficulties patients had in finding an appointment with their general practitioners. On the other hand, both in France and Portugal, the first year of pandemics did not worsen CRC staging at diagnosis and did not significantly affect medical and surgical treatments once the diagnosis was made.</p>","PeriodicalId":51838,"journal":{"name":"GE Portuguese Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2023-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249522/pdf/","citationCount":"0","resultStr":"{\"title\":\"Portuguese Results of the ETICC Study: Impact of the Pandemic COVID-19 in the Diagnosis and Management of Colorectal Cancer in 2020 in Portuguese Hospitals.\",\"authors\":\"Maria Ana Rafael, Cristiana Sequeira, Sónia Isabel da Silva Barros, Bárbara Silva Abreu, Cristina Teixeira, Pierre Lahmek, Marine Besnard, Bruno Lesgourgues\",\"doi\":\"10.1159/000531234\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The outbreak of coronavirus disease 2019 (COVID-19) had affected clinical practice in several ways, including the restriction of nonessential endoscopic procedures. Therefore, our aim was to evaluate how colorectal cancer (CRC) diagnosis and management was affected during the first year of pandemics in Portugal.</p><p><strong>Methods: </strong>This is a Portuguese substudy of the French retrospective multicentric study ETICC (<i>Etude de l'Impact de la pandémie COVID-19 sur le diagnostic et la prise en charge du Cancer Colorectal</i>). We compared patients' characteristics, clinical manifestations, CRC staging at diagnosis, delay to first medical appointment, histological diagnosis, surgical and medical treatments between the year previous to the pandemics (control) and the first year of pandemics.</p><p><strong>Results: </strong>We included 766 patients: 496 in the control group and 270 in the COVID group. There was no significant difference in CRC staging at diagnosis between both groups, with 21% being diagnosed as metastatic in the control group and 22% in the first year of pandemics (<i>p</i> = 0.770). Contrary to what happened in France, there was a significant decrease in CRC diagnosis in asymptomatic patients (25-8.4%; <i>p</i> < 0.001) and after a positive fecal immunochemical test (20.8-11.3%; <i>p</i> = 0.002) during the pandemics. Although the increase in the overall complication rate at diagnosis was nonsignificant, in Portugal, there was a significant increase in diagnosis of abdominal occlusion (12.1-18.1%; <i>p</i> = 0.033). In Portugal, time between the beginning of symptoms and the first medical appointment significantly increased from a median of 50 days to 64 days during COVID (<i>p</i> < 0.001). On the contrary, time between histological diagnosis and tumor resection had significantly decreased from a median of 65 to 39 days (<i>p</i> < 0.001). Time between histological diagnosis and neoadjuvant treatment was not statistically different (median of 64-67 days; <i>p</i> = 0.590), as was time between histological diagnosis and palliative chemotherapy (median of 50-51 days; <i>p</i> = 1.000). Time from CRC resection and adjuvant treatment has significantly decreased from a median of 54 to 43 days (<i>p</i> = 0.001).</p><p><strong>Discussion: </strong>We found a significant impact in CRC diagnosis in the first year of pandemics, more pronounced than what was found in France. These are likely related not only with the closing of endoscopy units but also with the difficulties patients had in finding an appointment with their general practitioners. On the other hand, both in France and Portugal, the first year of pandemics did not worsen CRC staging at diagnosis and did not significantly affect medical and surgical treatments once the diagnosis was made.</p>\",\"PeriodicalId\":51838,\"journal\":{\"name\":\"GE Portuguese Journal of Gastroenterology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2023-07-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249522/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GE Portuguese Journal of Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000531234\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GE Portuguese Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000531234","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言:冠状病毒病 2019(COVID-19)的爆发在多个方面影响了临床实践,包括限制非必要的内窥镜手术。因此,我们的目的是评估葡萄牙大流行第一年期间结直肠癌(CRC)诊断和管理受到的影响:这是法国回顾性多中心研究 ETICC(Etude de l'Impact de la pandémie COVID-19 sur le diagnostic et la prise en charge du Cancer Colorectal)的葡萄牙子研究。我们比较了大流行前一年(对照组)与大流行第一年之间患者的特征、临床表现、诊断时的 CRC 分期、首次就诊时间、组织学诊断、手术和药物治疗:我们纳入了 766 名患者:对照组 496 人,COVID 组 270 人。两组患者在确诊时的癌症分期没有明显差异,对照组中有 21% 的患者被诊断为转移性癌症,而在大流行的第一年则有 22% 的患者被诊断为转移性癌症(P = 0.770)。与法国的情况相反,在大流行期间,无症状患者(25-8.4%;p < 0.001)和粪便免疫化学检验阳性患者(20.8-11.3%;p = 0.002)的 CRC 诊断率显著下降。虽然确诊时的总体并发症发生率没有显著增加,但在葡萄牙,腹腔闭塞的确诊率显著增加(12.1%-18.1%;p = 0.033)。在葡萄牙,从开始出现症状到首次就诊的时间从 COVID 期间的中位数 50 天显著增加到 64 天(p < 0.001)。相反,从组织学诊断到肿瘤切除的时间从中位数 65 天大幅缩短至 39 天(p < 0.001)。组织学诊断与新辅助治疗之间的时间无统计学差异(中位数为 64-67 天;p = 0.590),组织学诊断与姑息化疗之间的时间也无统计学差异(中位数为 50-51 天;p = 1.000)。从癌症切除到辅助治疗的时间从中位数 54 天显著缩短至 43 天(p = 0.001):讨论:我们发现,大流行第一年对 CRC 诊断的影响很大,比在法国发现的更明显。这可能不仅与内窥镜检查机构的关闭有关,还与患者在与全科医生预约时遇到的困难有关。另一方面,在法国和葡萄牙,大流行的第一年并没有使诊断时的癌症分期恶化,也没有明显影响诊断后的内外科治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Portuguese Results of the ETICC Study: Impact of the Pandemic COVID-19 in the Diagnosis and Management of Colorectal Cancer in 2020 in Portuguese Hospitals.

Introduction: The outbreak of coronavirus disease 2019 (COVID-19) had affected clinical practice in several ways, including the restriction of nonessential endoscopic procedures. Therefore, our aim was to evaluate how colorectal cancer (CRC) diagnosis and management was affected during the first year of pandemics in Portugal.

Methods: This is a Portuguese substudy of the French retrospective multicentric study ETICC (Etude de l'Impact de la pandémie COVID-19 sur le diagnostic et la prise en charge du Cancer Colorectal). We compared patients' characteristics, clinical manifestations, CRC staging at diagnosis, delay to first medical appointment, histological diagnosis, surgical and medical treatments between the year previous to the pandemics (control) and the first year of pandemics.

Results: We included 766 patients: 496 in the control group and 270 in the COVID group. There was no significant difference in CRC staging at diagnosis between both groups, with 21% being diagnosed as metastatic in the control group and 22% in the first year of pandemics (p = 0.770). Contrary to what happened in France, there was a significant decrease in CRC diagnosis in asymptomatic patients (25-8.4%; p < 0.001) and after a positive fecal immunochemical test (20.8-11.3%; p = 0.002) during the pandemics. Although the increase in the overall complication rate at diagnosis was nonsignificant, in Portugal, there was a significant increase in diagnosis of abdominal occlusion (12.1-18.1%; p = 0.033). In Portugal, time between the beginning of symptoms and the first medical appointment significantly increased from a median of 50 days to 64 days during COVID (p < 0.001). On the contrary, time between histological diagnosis and tumor resection had significantly decreased from a median of 65 to 39 days (p < 0.001). Time between histological diagnosis and neoadjuvant treatment was not statistically different (median of 64-67 days; p = 0.590), as was time between histological diagnosis and palliative chemotherapy (median of 50-51 days; p = 1.000). Time from CRC resection and adjuvant treatment has significantly decreased from a median of 54 to 43 days (p = 0.001).

Discussion: We found a significant impact in CRC diagnosis in the first year of pandemics, more pronounced than what was found in France. These are likely related not only with the closing of endoscopy units but also with the difficulties patients had in finding an appointment with their general practitioners. On the other hand, both in France and Portugal, the first year of pandemics did not worsen CRC staging at diagnosis and did not significantly affect medical and surgical treatments once the diagnosis was made.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
GE Portuguese Journal of Gastroenterology
GE Portuguese Journal of Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
1.60
自引率
11.10%
发文量
62
审稿时长
21 weeks
期刊介绍: The ''GE Portuguese Journal of Gastroenterology'' (formerly Jornal Português de Gastrenterologia), founded in 1994, is the official publication of Sociedade Portuguesa de Gastrenterologia (Portuguese Society of Gastroenterology), Sociedade Portuguesa de Endoscopia Digestiva (Portuguese Society of Digestive Endoscopy) and Associação Portuguesa para o Estudo do Fígado (Portuguese Association for the Study of the Liver). The journal publishes clinical and basic research articles on Gastroenterology, Digestive Endoscopy, Hepatology and related topics. Review articles, clinical case studies, images, letters to the editor and other articles such as recommendations or papers on gastroenterology clinical practice are also considered. Only articles written in English are accepted.
期刊最新文献
Portuguese Pancreatic Club Perspectives on Pancreatic Neuroendocrine Neoplasms: Diagnosis and Staging, Associated Genetic Syndromes and Particularities of Their Clinical Approach. Lower Gastrointestinal Bleeding after Gynecological Surgery: An Atypical Endoscopic Diagnosis. Portuguese Pancreatic Club Perspectives on Endoscopic Ultrasound-Guided and Surgical Treatment of Pancreatic Neuroendocrine Tumors Schwannoma of Common Bile Duct: A Clinico-Radiologic Diagnostic Quagmire – A Case Report Endoscopic Mucosal Resection Using Band Ligation of a Duodenal Neuroendocrine Tumor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1